Archive: May 2021

The Use of Telemedicine in Hematology and Oncology

William Wood, MD

H&O  What exactly does telemedicine encompass? WW  Telemedicine can include a variety of components of health care delivered virtually. Since the beginning of the pandemic last […]

Chimeric Antigen Receptor T-Cell Therapy Plus Checkpoint Blockade in Thoracic Cancers

Prasad S. Adusumilli, MD, FACS, FCCP

H&O How has immunotherapy impacted outcome in thoracic cancers? PA  In the past 5 years, knowledge of immunology in thoracic cancers has greatly improved. The results […]

What’s Next for Immunotherapy in Locally Advanced NSCLC?

Neal Edward Ready, MD, PhD

H&O  Which immunotherapy agents have been approved for use in locally advanced non–small cell lung cancer? NR  Durvalumab (Imfinzi, AstraZeneca) is the only agent to have […]

The Evolving Role of Immune Checkpoint Inhibitors in the Treatment of Triple-Negative Breast Cancer

Meghan Steiner, MD, and Antoinette R. Tan, MD, MHSc

Abstract: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer for which chemotherapy had been the only active treatment option once metastatic disease developed. […]

Lenalidomide in DLBCL: Are We Past the Cell of Origin?

Mendel Goldfinger, MD, and Dennis L. Cooper, MD

Abstract: Single-agent lenalidomide has modest activity in diffuse large B-cell lymphoma (DLBCL) and is thought to be more potent in activated B-cell (ABC) lymphomas, which are […]

Recently Approved Drugs Herald a New Era in Therapy for Diffuse Large B-Cell Lymphoma

Grzegorz S. Nowakowski, MD

H&O  What are the standard treatments for diffuse large B-cell lymphoma (DLBCL)? GN  For nearly 20 years, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has […]

Letter from the Editor: The Too-Typical Clinical Conundrum

Richard R. Furman, MD

In the March issue, I wrote about a patient who had a lot to teach me about life. This month, I am writing about a different […]

Back to Archive